Cargando…

Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?

The response of severe chronic spontaneous urticaria (CSU) to omalizumab largely depends on the autoimmune or autoallergic endotype of the disease. Whether thyroid autoimmunity may predict omalizumab response along with total IgE in CSU is still unclear. Three hundred and eighty-five patients (M/F 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Asero, Riccardo, Ferrucci, Silvia Mariel, Calzari, Paolo, Consonni, Dario, Cugno, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139159/
https://www.ncbi.nlm.nih.gov/pubmed/37108654
http://dx.doi.org/10.3390/ijms24087491
_version_ 1785032879377481728
author Asero, Riccardo
Ferrucci, Silvia Mariel
Calzari, Paolo
Consonni, Dario
Cugno, Massimo
author_facet Asero, Riccardo
Ferrucci, Silvia Mariel
Calzari, Paolo
Consonni, Dario
Cugno, Massimo
author_sort Asero, Riccardo
collection PubMed
description The response of severe chronic spontaneous urticaria (CSU) to omalizumab largely depends on the autoimmune or autoallergic endotype of the disease. Whether thyroid autoimmunity may predict omalizumab response along with total IgE in CSU is still unclear. Three hundred and eighty-five patients (M/F 123/262; mean age 49.5 years; range 12–87 years) with severe CSU were studied. Total IgE levels and thyroid autoimmunity (levels of anti-thyroid peroxidase [TPO] IgG) were measured before omalizumab treatment. Based on the clinical response, patients were divided into early (ER), late (LR), partial (PR) and non (NR) responders to omalizumab. Thyroid autoimmunity was detected in 92/385 (24%) patients. Altogether, 52%, 22%, 16% and 10% of patients were ER, LR, PR and NR to omalizumab, respectively. Response to omalizumab was not associated with thyroid autoimmunity (p = 0.77). Conversely, we found a strongly positive association between IgE levels and omalizumab response (p < 0.0001); this association was largely driven by early response (OR = 5.46; 95% CI: 2.23–13.3). Moreover, the predicted probabilities of early response strongly increased with increasing IgE levels. Thyroid autoimmunity alone cannot be used as a clinical predictor of omalizumab response. Total IgE levels remain the only and most reliable prognostic marker for omalizumab response in patients with severe CSU.
format Online
Article
Text
id pubmed-10139159
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101391592023-04-28 Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? Asero, Riccardo Ferrucci, Silvia Mariel Calzari, Paolo Consonni, Dario Cugno, Massimo Int J Mol Sci Communication The response of severe chronic spontaneous urticaria (CSU) to omalizumab largely depends on the autoimmune or autoallergic endotype of the disease. Whether thyroid autoimmunity may predict omalizumab response along with total IgE in CSU is still unclear. Three hundred and eighty-five patients (M/F 123/262; mean age 49.5 years; range 12–87 years) with severe CSU were studied. Total IgE levels and thyroid autoimmunity (levels of anti-thyroid peroxidase [TPO] IgG) were measured before omalizumab treatment. Based on the clinical response, patients were divided into early (ER), late (LR), partial (PR) and non (NR) responders to omalizumab. Thyroid autoimmunity was detected in 92/385 (24%) patients. Altogether, 52%, 22%, 16% and 10% of patients were ER, LR, PR and NR to omalizumab, respectively. Response to omalizumab was not associated with thyroid autoimmunity (p = 0.77). Conversely, we found a strongly positive association between IgE levels and omalizumab response (p < 0.0001); this association was largely driven by early response (OR = 5.46; 95% CI: 2.23–13.3). Moreover, the predicted probabilities of early response strongly increased with increasing IgE levels. Thyroid autoimmunity alone cannot be used as a clinical predictor of omalizumab response. Total IgE levels remain the only and most reliable prognostic marker for omalizumab response in patients with severe CSU. MDPI 2023-04-19 /pmc/articles/PMC10139159/ /pubmed/37108654 http://dx.doi.org/10.3390/ijms24087491 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Asero, Riccardo
Ferrucci, Silvia Mariel
Calzari, Paolo
Consonni, Dario
Cugno, Massimo
Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
title Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
title_full Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
title_fullStr Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
title_full_unstemmed Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
title_short Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
title_sort thyroid autoimmunity in csu: a potential marker of omalizumab response?
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139159/
https://www.ncbi.nlm.nih.gov/pubmed/37108654
http://dx.doi.org/10.3390/ijms24087491
work_keys_str_mv AT aseroriccardo thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse
AT ferruccisilviamariel thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse
AT calzaripaolo thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse
AT consonnidario thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse
AT cugnomassimo thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse